Aptinyx To Go Ex-Dividend On January 2nd, 2024 With 0.09869 USD Dividend Per Share
December 27th - $Aptinyx(APTX.US)$ is trading ex-dividend on January 2nd, 2024. Shareholders of record on December 26th, 2023 will receive 0.09869 USD dividend per share on December 29th, 2023. Th
moomoo NewsDec 26, 2023 19:55 ET
Parkinson's Disease Psychosis Market Is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight | Key Companies Working to Develop Therapies - Vanda, Kyowa Kirin, Sage, Athira, Aptinyx, CogState, AgeneBio
The dynamics of the Parkinson's disease psychosis market are anticipated to change in the coming years owing to the improvement in diagnosis methodologies, rising awareness of the disease, incrementa
PR NewswireOct 2, 2023 17:01 ET
Aptinyx Inc. (APTX) Witnesses Remarkable Recovery Amidst Challenges
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company specializing in brain and nervous system disorder treatments, is experiencing an astonishing after-market price surge. Despite a challenging day, the stock is making an epic recovery, soaring by an impressive 21% after hours. This unexpected jump is capturing attention and raising speculation about the factors driving Aptinyx ...
Stocks TelegraphMay 19, 2023 03:43 ET
Short Interest in Aptinyx Inc. (NASDAQ:APTX) Decreases By 11.6%
Aptinyx Inc. (NASDAQ:APTX – Get Rating) saw a significant decrease in short interest in April. As of April 15th, there was short interest totalling 2,890,000 shares, a decrease of 11.6% from the Marc
kopsourceApr 30, 2023 08:34 ET
Aptinyx Inc. (NASDAQ:APTX) Expected to Post Q1 2024 Earnings of ($0.06) Per Share
Aptinyx Inc. (NASDAQ:APTX – Get Rating) – William Blair issued their Q1 2024 EPS estimates for Aptinyx in a research note issued on Friday, March 31st. William Blair analyst M. Minter forecasts tha
Defense WorldApr 3, 2023 02:22 ET
Stocks That Hit 52-Week Lows On Friday
 On Friday, 93 stocks made new 52-week lows. Noteworthy Points From Today's 52-Week Lows: Canopy Gwth (NASDAQ:CGC) was the largest, in terms of market cap, to set a new 52-week low.Biodexa Pharmace
BenzingaMar 31, 2023 11:46 ET
Aptinyx Evaluates Strategic Alternatives For Its Future After Failed Trials, 60% Layoffs
In March, Aptinyx Inc (NASDAQ:APTX) completed an analysis of the data from the first 100 patients enrolled in its Phase 2b clinical study of NYX-783 50 mg in patients with post-traumatic stress disord
BenzingaMar 31, 2023 10:33 ET
Aptinyx Q4 EPS $(0.18) Beats $(0.19) Estimate
Aptinyx (NASDAQ:APTX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 37.93 percent increase over losses of $(0.29) per s
BenzingaMar 30, 2023 16:50 ET
Express News | Aptinyx 4Q Loss $12.1M >APTX
Moomoo 24/7Mar 30, 2023 16:05 ET
Express News | Aptinyx 4Q Loss/Shr 18c >APTX
Moomoo 24/7Mar 30, 2023 16:05 ET
Here's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock Now
Yahoo FinanceMar 30, 2023 11:20 ET
12 Health Care Stocks Moving In Friday's Intraday Session
GainerselectroCore (NASDAQ:ECOR) shares increased by 27.9% to $5.47 during Friday's regular session. As of 13:30 EST, electroCore's stock is trading at a volume of 91.3K, which is 434.3% of its averag
BenzingaMar 24, 2023 13:31 ET
Dermata DRMA Analyst; Aptinyx APTX EU Patent
BioPharmCatalystMar 24, 2023 08:22 ET
Aptinyx Granted European Patent Titled 'Spiro-lactam Nmda Receptor Modulators And Uses Thereof (for The Treatment Of Conditions Such As Depression And Related Disorders)'
Aptinyx Granted European Patent Titled 'Spiro-lactam Nmda Receptor Modulators And Uses Thereof (for The Treatment Of Conditions Such As Depression And Related Disorders)'
BenzingaMar 23, 2023 16:01 ET
HC Wainwright Lowers Aptinyx (NASDAQ:APTX) to Neutral
HC Wainwright cut shares of Aptinyx (NASDAQ:APTX – Get Rating) from a buy rating to a neutral rating in a report published on Tuesday morning, The Fly reports. HC Wainwright also issued estimates for
Financial News LiveMar 10, 2023 04:33 ET
Aptinyx (NASDAQ:APTX) Downgraded to Neutral at HC Wainwright
HC Wainwright cut shares of Aptinyx (NASDAQ:APTX – Get Rating) from a buy rating to a neutral rating in a research note published on Tuesday, The Fly reports. HC Wainwright also issued estimates for A
kopsourceMar 10, 2023 04:32 ET
Equities Research Analysts' Downgrades for March 7th (ANIK, APTX, CDNA, CKN, CKNHF, COLL, E, EMBK, ETN, FMS)
Equities Research Analysts' downgrades for Tuesday, March 7th:Anika Therapeutics (NASDAQ:ANIK) was downgraded by analysts at Barrington Research from an outperform rating to a market perform rating.
Financial News LiveMar 7, 2023 13:43 ET
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
UpgradesCraig-Hallum upgraded the previous rating for Carrols Restaurant Group Inc (NASDAQ:TAST) from Hold to Buy. In the fourth quarter, Carrols Restaurant Group showed an EPS of $0.05, compared to $
BenzingaMar 7, 2023 10:03 ET
Aptinyx Cut to Neutral From Buy by HC Wainwright & Co.
Aptinyx Cut to Neutral From Buy by HC Wainwright & Co.
Dow JonesMar 7, 2023 06:28 ET
HC Wainwright & Co. Downgrades Aptinyx to Neutral
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Aptinyx (NASDAQ:APTX) from Buy to Neutral.
BenzingaMar 7, 2023 06:18 ET
No Data
No Data